ENDP vs. CALA, SCPS, ATHX, APVO, AMPE, OBSV, ALLR, SXTC, ADTX, and PTEIQ
Should you be buying Endo International stock or one of its competitors? The main competitors of Endo International include Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Athersys (ATHX), Aptevo Therapeutics (APVO), Ampio Pharmaceuticals (AMPE), ObsEva (OBSV), Allarity Therapeutics (ALLR), China SXT Pharmaceuticals (SXTC), Aditxt (ADTX), and PolarityTE (PTEIQ). These companies are all part of the "medical" sector.
Endo International (NASDAQ:ENDP) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
Calithera Biosciences has lower revenue, but higher earnings than Endo International.
Endo International has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500.
Calithera Biosciences has a net margin of 0.00% compared to Endo International's net margin of -93.31%. Calithera Biosciences' return on equity of 0.00% beat Endo International's return on equity.
Endo International received 580 more outperform votes than Calithera Biosciences when rated by MarketBeat users. Likewise, 63.74% of users gave Endo International an outperform vote while only 59.82% of users gave Calithera Biosciences an outperform vote.
In the previous week, Endo International had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 2 mentions for Endo International and 1 mentions for Calithera Biosciences. Calithera Biosciences' average media sentiment score of 0.13 beat Endo International's score of 0.01 indicating that Calithera Biosciences is being referred to more favorably in the news media.
80.4% of Endo International shares are held by institutional investors. 1.2% of Endo International shares are held by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Endo International beats Calithera Biosciences on 7 of the 13 factors compared between the two stocks.
Get Endo International News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Endo International Competitors List
Related Companies and Tools
